Expansion is fueled by adoption of targeted biologics, oncolytic virus therapies, rising prevalence in Asia-Pacific, and improved healthcare access. North America leads in market share, while Asia-Pacific exhibits fastest growth. https://www.datamintelligence.com/research-report/retinoblastoma-market